Leerink Swann Downgrades Inspire Pharma (ISPH) to Market Perform; Denufosol Failure Removes Main Source of Upside
Tweet Send to a Friend
Leerink Swann downgraded Inspire Pharma (NASDAQ: ISPH) to Market Perform. PT cut from $10 to $4.
Leerink analyst says, "ISPH ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Leerink analyst says, "ISPH ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
